ArticleFrontiers in medicine2026
Evaluation of eradication efficacy and optimization strategies for
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Based on real-world clinical data, this study aims to evaluate the differences in eradication efficacy among various Methods: This single-center retrospective study included 897 patients with confirmed Results: Overall ITT and PP eradication rates were 79.04 and 90.23%, respectively. Quadruple therapy achieved the highest rates (ITT: 81.42%; PP: 93.76%), outperforming dual and triple therapies. Prescription appropriateness significantly affected eradication in the quadruple therapy group ( Conclusion: Clinical practice should prioritize guideline-recommended regimens and standards; however, actual eradication effectiveness may vary depending on the regimen selected. Among these, bismuth-containing quadruple therapy should be the first-line treatment of choice and should be used in strict accordance with guideline standards.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.